These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 19489856

  • 1. Erythema multiforme induced by sorafenib.
    Feltes RA, Feito Rodríguez M, González-Beato MJ.
    Clin Exp Dermatol; 2009 Oct; 34(7):e368-9. PubMed ID: 19489856
    [No Abstract] [Full Text] [Related]

  • 2. Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma.
    Bilaç C, Müezzinoğlu T, Ermertcan AT, Kayhan TC, Temeltaş G, Oztürkcan S, Temiz P.
    Cutan Ocul Toxicol; 2009 Oct; 28(2):90-2. PubMed ID: 19514932
    [Abstract] [Full Text] [Related]

  • 3. Non-pigmenting fixed drug eruption induced by sorafenib.
    Tanabe K, Amoh Y, Mii S, Eto H, Iwamura M, Katsuoka K.
    Acta Derm Venereol; 2010 May; 90(3):307. PubMed ID: 20526556
    [No Abstract] [Full Text] [Related]

  • 4. Erythema multiforme induced by sorafenib for metastatic renal cell carcinoma.
    Ikeda M, Fujita T, Mii S, Tanabe K, Tabata K, Matsumoto K, Satoh T, Iwamura M.
    Jpn J Clin Oncol; 2012 Sep; 42(9):820-4. PubMed ID: 22782962
    [Abstract] [Full Text] [Related]

  • 5. Sorafenib-induced erythema multiforme: three cases.
    Namba M, Tsunemi Y, Kawashima M.
    Eur J Dermatol; 2011 Sep; 21(6):1015-6. PubMed ID: 21926043
    [No Abstract] [Full Text] [Related]

  • 6. Hand-foot and stump syndrome to sorafenib.
    Lai SE, Kuzel T, Lacouture ME.
    J Clin Oncol; 2007 Jan 20; 25(3):341-3. PubMed ID: 17235051
    [No Abstract] [Full Text] [Related]

  • 7. Sorafenib-induced erythema multiforme for metastatic renal cell carcinoma.
    Kodaira M, Takahashi S, Takeuchi K, Yuasa T, Saotome T, Yonese J, Fukui I, Hatake K.
    Ann Oncol; 2010 Jul 20; 21(7):1563-1565. PubMed ID: 20573851
    [No Abstract] [Full Text] [Related]

  • 8. Chloracne-like drug eruption associated with sorafenib.
    Pickert A, Hughes M, Wells M.
    J Drugs Dermatol; 2011 Nov 20; 10(11):1331-4. PubMed ID: 22052319
    [Abstract] [Full Text] [Related]

  • 9. Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib.
    Beldner M, Jacobson M, Burges GE, Dewaay D, Maize JC, Chaudhary UB.
    Oncologist; 2007 Oct 20; 12(10):1178-82. PubMed ID: 17962611
    [Abstract] [Full Text] [Related]

  • 10. Sorafenib: atypical cutaneous side effects.
    Richetta AG, Maiani E, Carboni V, Carlomagno V, Cimillo M, Mattozzi C, Calvieri S.
    Eur J Dermatol; 2007 Oct 20; 17(6):549-50. PubMed ID: 17951148
    [No Abstract] [Full Text] [Related]

  • 11. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
    Autier J, Escudier B, Wechsler J, Spatz A, Robert C.
    Arch Dermatol; 2008 Jul 20; 144(7):886-92. PubMed ID: 18645140
    [Abstract] [Full Text] [Related]

  • 12. [Application monitoring of the use of sorafenib in papillary renal cell carcinoma].
    Schrader AJ, Hegele A, Olbert P, Buer J, Jeron A, Hofmann R.
    Urologe A; 2007 Sep 20; 46(9):1291. PubMed ID: 17668165
    [No Abstract] [Full Text] [Related]

  • 13. Transient perforating folliculitis induced by sorafenib.
    Minami-Hori M, Ishida-Yamamoto A, Komatsu S, Iiduka H.
    J Dermatol; 2010 Sep 20; 37(9):833-4. PubMed ID: 20883372
    [No Abstract] [Full Text] [Related]

  • 14. Cutaneous drug eruptions induced by sorafenib: a case series.
    Maddox JS, Kung EF, Petronic-Rosic V, Sethi A.
    J Drugs Dermatol; 2008 Sep 20; 7(9):891-3. PubMed ID: 19112807
    [Abstract] [Full Text] [Related]

  • 15. Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma.
    Eng FC, Easson AM, Szentgyorgyi E, Knox JJ.
    Eur J Surg Oncol; 2009 Feb 20; 35(2):219-21. PubMed ID: 17976949
    [No Abstract] [Full Text] [Related]

  • 16. Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET.
    Hutson TE, Bellmunt J, Porta C, Szczylik C, Staehler M, Nadel A, Anderson S, Bukowski R, Eisen T, Escudier B, Sorafenib TARGET Clinical Trial Group.
    Eur J Cancer; 2010 Sep 20; 46(13):2432-40. PubMed ID: 20656473
    [Abstract] [Full Text] [Related]

  • 17. Sorafenib-induced erythema multiforme.
    MacGregor JL, Silvers DN, Grossman ME, Sherman WH.
    J Am Acad Dermatol; 2007 Mar 20; 56(3):527-8. PubMed ID: 17241689
    [No Abstract] [Full Text] [Related]

  • 18. Sorafenib-induced palmoplantar hyperkeratosis.
    Lountzis NI, Maroon MS.
    J Drugs Dermatol; 2008 Jun 20; 7(6):588-9. PubMed ID: 18561593
    [Abstract] [Full Text] [Related]

  • 19. Erythema multiforme-like drug reaction to sorafenib.
    Lewin J, Farley-Loftus R, Pomeranz MK.
    J Drugs Dermatol; 2011 Dec 20; 10(12):1462-3. PubMed ID: 22134572
    [Abstract] [Full Text] [Related]

  • 20. The histologic spectrum of epithelial neoplasms induced by sorafenib.
    Kwon EJ, Kish LS, Jaworsky C.
    J Am Acad Dermatol; 2009 Sep 20; 61(3):522-7. PubMed ID: 19700018
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.